

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative:**

**National HIV Surveillance System Data
Reported Through June 2024**



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for HIV diagnoses reported to CDC through June 2024.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through June 2024. *HIV Surveillance Data Tables* 2024;5(3). <https://stacks.cdc.gov/view/cdc/162350>. Published September 2024. Accessed [date].

On the Web: <https://www.cdc.gov/hiv-data/initiatives/>

Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Taylor Jones, Zanetta Gant Sumner, Maya Zvavitch, Xueyuan Dong, Chan Jin, Xiaohong Hu, Jianmin Li, Stacy Cohen, and Michael Friend (editing and desktop publishing).

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through June 2024—United States (preliminary)	7
1b HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through June 2024—United States and 6 territories and freely associated states (preliminary)	8
1c HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—United States and 6 territories and freely associated states (preliminary)	9
1d HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2023 through March 2024—48 states and the District of Columbia (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—48 states and the District of Columbia (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3 Ending the HIV Epidemic Phase I jurisdictions	19

Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core indicators for monitoring the Ending the HIV Epidemic initiative* report, available at <https://www.cdc.gov/hiv-data/initiatives/>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care for the years 2023 and 2024 based on cases reported to CDC as of June 2024. Data for the 2 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes of the *HIV Surveillance Report, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>.

TABULATION AND PRESENTATION OF DATA

HIV Diagnoses

HIV diagnoses are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2023 through June 2024 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the years 2023 and 2024 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the *HIV Surveillance Report, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years with HIV diagnosed during January 2023 through March 2024 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2023 through March 2024 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2023 through March 2024. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to the National HIV Surveillance System (NHSS); therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2023 through March 2024 and reported to NHSS through June 2024. Data for the years 2023

and 2024 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Data for Mississippi and West Virginia were included in analyses but should also be interpreted with caution due to a lapse in laboratory reporting that occurred during the year 2022.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-outcomes.html>.

References

1. HHS. EHE Overview. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated December 2023. Accessed September 6, 2024.

Table 1a. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through June 2024—United States (preliminary)

	No. 2023	No. 2024 (January–June)
Gender		
Man	30,325	11,937
Woman	7,283	3,051
Transgender woman ^a	756	290
Transgender man ^a	70	27
Additional gender identity ^b	101	25
Age at diagnosis (yr)		
13–24	7,018	2,639
25–34	14,147	5,658
35–44	8,799	3,567
45–54	4,742	1,878
55–64	2,882	1,146
≥65	954	448
Race/ethnicity		
American Indian/Alaska Native	205	80
Asian	800	307
Black/African American	14,763	6,327
Hispanic/Latino ^c	12,809	4,867
Native Hawaiian/other Pacific Islander	58	38
White	8,971	3,449
Multiracial	936	268
Transmission category^d		
Male-to-male sexual contact ^e	25,613	10,129
Injection drug use ^f		
Male	1,383	516
Female	1,080	398
Male-to-male sexual contact ^e and injection drug use ^f	1,317	444
Heterosexual contact ^g		
Male	2,839	1,151
Female	6,236	2,663
Other ^h		
Male	32	15
Female	43	21
Region of residenceⁱ		
Northeast	5,187	1,999
Midwest	5,199	2,124
South	20,300	8,550
West	7,856	2,663
Total^j	38,542	15,336

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman.

“Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

ⁱ Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^j Includes persons of unknown gender.

Table 1b. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2023 through June 2024—United States and 6 territories and freely associated states (preliminary)

	No. 2023	No. 2024 (January–June)
Gender		
Man	30,648	12,037
Woman	7,349	3,069
Transgender woman ^a	758	291
Transgender man ^a	70	27
Additional gender identity ^b	101	25
Age at diagnosis (yr)		
13–24	7,069	2,650
25–34	14,294	5,704
35–44	8,877	3,589
45–54	4,794	1,898
55–64	2,928	1,159
≥65	971	455
Race/ethnicity		
American Indian/Alaska Native	205	80
Asian	801	308
Black/African American	14,769	6,329
Hispanic/Latino ^c	13,183	4,980
Native Hawaiian/other Pacific Islander	58	40
White	8,980	3,450
Multiracial	937	268
Transmission category^d		
Male-to-male sexual contact ^e	25,861	10,203
Injection drug use ^f		
Male	1,395	522
Female	1,083	398
Male-to-male sexual contact ^e and injection drug use ^f	1,317	446
Heterosexual contact ^g		
Male	2,902	1,169
Female	6,299	2,681
Other ^h		
Male	32	15
Female	43	21
Region of residenceⁱ		
Northeast	5,187	1,999
Midwest	5,199	2,124
South	20,300	8,550
West	7,856	2,663
U.S. territories and freely associated states	391	119
Total^j	38,933	15,455

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau. Data are for cases reported to CDC through June 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

ⁱ Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^j Includes persons of unknown gender.

Table 1c. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—United States and 6 territories and freely associated states (preliminary)

Area of residence	No.	No.
	2023	2024 (January–June)
Alabama	696	230
Alaska	26	13
Arizona	967	324
Arkansas	303	199
California	4,644	1,438
Colorado	476	186
Connecticut	247	97
Delaware	103	53
District of Columbia	187	16
Florida	4,557	2,330
Georgia	2,372	1,074
Hawaii	56	25
Idaho	48	11
Illinois	1,388	437
Indiana	669	274
Iowa	138	50
Kansas	146	60
Kentucky	396	153
Louisiana	855	397
Maine	35	33
Maryland	713	328
Massachusetts	533	100
Michigan	697	344
Minnesota	320	152
Mississippi	505	188
Missouri	553	208
Montana	27	9
Nebraska	99	41
Nevada	558	208
New Hampshire	35	14
New Jersey	963	299
New Mexico	183	26
New York	2,371	1,023
North Carolina	1,405	676
North Dakota	21	7
Ohio	860	428
Oklahoma	355	91
Oregon	242	78
Pennsylvania	931	387
Rhode Island	64	42
South Carolina	912	202
South Dakota	51	9
Tennessee	898	370
Texas	5,076	1,808
Utah	175	112
Vermont	8	4
Virginia	870	390
Washington	433	227
West Virginia	97	45
Wisconsin	257	114
Wyoming	21	6
Subtotal	38,542	15,336
U.S. territories and freely associated states		
American Samoa	0	0
Guam	3	3
Northern Mariana Islands	0	0
Puerto Rico	378	115
Republic of Palau	0	0
U.S. Virgin Islands	10	1
Subtotal	391	119
Total	38,933	15,455

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through June 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	No.	
	2023	2024 (January–June)
Arizona		
Maricopa County	634	210
California		
Alameda County	186	75
Los Angeles County	1,564	513
Orange County	262	91
Riverside County	299	98
Sacramento County	141	10
San Bernardino County	279	61
San Diego County	381	122
San Francisco County	184	88
District of Columbia	187	16
Florida		
Broward County	568	305
Duval County	259	121
Hillsborough County	362	151
Miami-Dade County	1,045	521
Orange County	477	237
Palm Beach County	277	151
Pinellas County	155	95
Georgia		
Cobb County	164	67
DeKalb County	305	136
Fulton County	444	238
Gwinnett County	233	91
Illinois		
Cook County	949	309
Indiana		
Marion County	258	123
Louisiana		
East Baton Rouge Parish	127	62
Orleans Parish	128	69
Maryland		
Baltimore City	165	68
Montgomery County	98	43
Prince George's County	193	78
Massachusetts		
Suffolk County	142	19
Michigan		
Wayne County	294	154
Nevada		
Clark County	498	185
New Jersey		
Essex County	198	66
Hudson County	116	34

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2023 through June 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	No.	No.
	2023 (<i>cont</i>)	2024 (January–June) (<i>cont</i>)
New York		
Bronx County	411	172
Kings County	475	219
New York County	301	143
Queens County	434	154
North Carolina		
Mecklenburg County	272	143
Ohio		
Cuyahoga County	146	78
Franklin County	209	70
Hamilton County	105	43
Pennsylvania		
Philadelphia County	373	167
Puerto Rico		
San Juan Municipio	88	29
Tennessee		
Shelby County	352	124
Texas		
Bexar County	390	117
Dallas County	842	401
Harris County	1,322	496
Tarrant County	342	144
Travis County	219	102
Washington		
King County	177	104
Total	18,030	7,313

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through June 2024. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2023 through March 2024—48 states and the District of Columbia (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023				
Gender					
Man	29,511	24,552	83.2	4,959	16.8
Woman	7,101	5,802	81.7	1,299	18.3
Transgender woman ^a	744	649	87.2	95	12.8
Transgender man ^a	69	61	88.4	8	11.6
Additional gender identity ^b	99	89	89.9	10	10.1
Age at diagnosis (yr)					
13–24	6,859	5,626	82.0	1,233	18.0
25–34	13,773	11,470	83.3	2,303	16.7
35–44	8,566	7,093	82.8	1,473	17.2
45–54	4,600	3,853	83.8	747	16.2
55–64	2,803	2,338	83.4	465	16.6
≥65	930	778	83.7	152	16.3
Race/ethnicity					
American Indian/Alaska Native	203	171	84.2	32	15.8
Asian	781	675	86.4	106	13.6
Black/African American	14,427	11,569	80.2	2,858	19.8
Hispanic/Latino ^c	12,321	10,527	85.4	1,794	14.6
Native Hawaiian/other Pacific Islander	58	51	87.9	7	12.1
White	8,830	7,400	83.8	1,430	16.2
Multiracial	911	765	84.0	146	16.0
Transmission category^d					
Male-to-male sexual contact ^e	24,985	20,970	83.9	4,015	16.1
Injection drug use ^f	2,383	1,870	78.5	513	21.5
Male	1,322	1,028	77.8	294	22.2
Female	1,061	842	79.4	218	20.6
Male-to-male sexual contact ^e and injection drug use ^f	1,293	1,039	80.4	254	19.6
Heterosexual contact ^g	8,798	7,219	82.1	1,579	17.9
Male	2,724	2,229	81.8	495	18.2
Female	6,074	4,990	82.2	1,083	17.8
Total^h	37,531	31,158	83.0	6,373	17.0

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2023 through March 2024—48 states and the District of Columbia (preliminary) (cont)

	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	
2024 (January–March)						
Gender						
Man	7,346	6,201	84.4	1,145	15.6	
Woman	1,837	1,523	82.9	314	17.1	
Transgender woman ^a	201	173	86.1	28	13.9	
Transgender man ^a	14	12	85.7	2	14.3	
Additional gender identity ^b	17	17	100	0	0.0	
Age at diagnosis (yr)						
13–24	1,633	1,333	81.6	300	18.4	
25–34	3,545	2,992	84.4	553	15.6	
35–44	2,115	1,808	85.5	307	14.5	
45–54	1,120	939	83.8	181	16.2	
55–64	731	625	85.5	106	14.5	
≥65	275	232	84.4	43	15.6	
Race/ethnicity						
American Indian/Alaska Native	49	42	85.7	7	14.3	
Asian	183	154	84.2	29	15.8	
Black/African American	3,836	3,137	81.8	699	18.2	
Hispanic/Latino ^c	3,046	2,645	86.8	401	13.2	
Native Hawaiian/other Pacific Islander	25	24	96.0	1	4.0	
White	2,114	1,781	84.2	333	15.8	
Multiracial	166	146	88.0	20	12.0	
Transmission category^d						
Male-to-male sexual contact ^e	6,246	5,291	84.7	956	15.3	
Injection drug use ^f	534	438	82.0	96	18.0	
Male	307	255	83.2	52	16.8	
Female	227	183	80.4	45	19.6	
Male-to-male sexual contact ^e and injection drug use ^f	284	241	84.7	43	15.3	
Heterosexual contact ^g	2,334	1,941	83.2	393	16.8	
Male	718	595	82.9	122	17.1	
Female	1,616	1,346	83.3	270	16.7	
Total^h	9,419	7,929	84.2	1,490	15.8	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are for cases reported to CDC through June 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

^a “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

^b Additional gender identity examples include “nonbinary,” “gender queer,” and “two-spirit.”

^c Hispanic/Latino persons can be of any race.

^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^e Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^g Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^h Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through March 2024—48 states and the District of Columbia (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023				
Alabama	696	580	83.3	116	16.7
Alaska	26	22	84.6	4	15.4
Arizona	967	796	82.3	171	17.7
Arkansas	303	260	85.8	43	14.2
California	4,644	3,954	85.1	690	14.9
Colorado	476	388	81.5	88	18.5
Connecticut	247	205	83.0	42	17.0
Delaware	103	84	81.6	19	18.4
District of Columbia	187	157	84.0	30	16.0
Florida	4,557	3,767	82.7	790	17.3
Georgia	2,372	1,950	82.2	422	17.8
Hawaii	56	45	80.4	11	19.6
Illinois	1,388	1,179	84.9	209	15.1
Indiana	669	520	77.7	149	22.3
Iowa	138	128	92.8	10	7.2
Kansas	146	119	81.5	27	18.5
Kentucky	396	325	82.1	71	17.9
Louisiana	855	709	82.9	146	17.1
Maine	35	33	94.3	2	5.7
Maryland	713	633	88.8	80	11.2
Massachusetts	533	481	90.2	52	9.8
Michigan	697	563	80.8	134	19.2
Minnesota	320	292	91.3	28	8.7
Mississippi ^a	505	387	76.6	118	23.4
Missouri	553	464	83.9	89	16.1
Montana	27	25	92.6	2	7.4
Nebraska	99	86	86.9	13	13.1
Nevada	558	463	83.0	95	17.0
New Hampshire	35	27	77.1	8	22.9
New Mexico	183	153	83.6	30	16.4
New York	2,371	2,050	86.5	321	13.5
North Carolina	1,405	1,114	79.3	291	20.7
North Dakota	21	18	85.7	3	14.3
Ohio	860	715	83.1	145	16.9
Oklahoma	355	296	83.4	59	16.6
Oregon	242	222	91.7	20	8.3
Pennsylvania	931	791	85.0	140	15.0
Rhode Island	64	58	90.6	6	9.4
South Carolina	912	802	87.9	110	12.1
South Dakota	51	44	86.3	7	13.7
Tennessee	898	629	70.0	269	30.0
Texas	5,076	4,073	80.2	1,003	19.8
Utah	175	136	77.7	39	22.3
Vermont	8	7	87.5	1	12.5
Virginia	870	720	82.8	150	17.2
Washington	433	373	86.1	60	13.9
West Virginia ^a	97	64	66.0	33	34.0
Wisconsin	257	231	89.9	26	10.1
Wyoming	21	20	95.2	1	4.8

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through March 2024—48 states and the District of Columbia (preliminary) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024 (January–March)				
Alabama	124	56	45.2	68	54.8
Alaska	6	5	83.3	1	16.7
Arizona	253	227	89.7	26	10.3
Arkansas	105	90	85.7	15	14.3
California	925	797	86.2	128	13.8
Colorado	117	83	70.9	34	29.1
Connecticut	68	60	88.2	8	11.8
Delaware	31	25	80.6	6	19.4
District of Columbia	14	12	85.7	2	14.3
Florida	1,356	1,132	83.5	224	16.5
Georgia	667	559	83.8	108	16.2
Hawaii	14	12	85.7	2	14.3
Illinois	338	295	87.3	43	12.7
Indiana	173	145	83.8	28	16.2
Iowa	29	25	86.2	4	13.8
Kansas	30	28	93.3	2	6.7
Kentucky	82	64	78.0	18	22.0
Louisiana	225	190	84.4	35	15.6
Maine	21	18	85.7	3	14.3
Maryland	208	190	91.3	18	8.7
Massachusetts	94	84	89.4	10	10.6
Michigan	194	172	88.7	22	11.3
Minnesota	92	83	90.2	9	9.8
Mississippi ^a	108	65	60.2	43	39.8
Missouri	116	97	83.6	19	16.4
Montana	9	8	88.9	1	11.1
Nebraska	26	24	92.3	2	7.7
Nevada	150	132	88.0	18	12.0
New Hampshire	8	4	50.0	4	50.0
New Mexico	22	17	77.3	5	22.7
New York	663	591	89.1	72	10.9
North Carolina	374	298	79.7	76	20.3
North Dakota	5	5	100	0	0.0
Ohio	246	211	85.8	35	14.2
Oklahoma	59	52	88.1	7	11.9
Oregon	43	37	86.0	6	14.0
Pennsylvania	234	202	86.3	32	13.7
Rhode Island	25	22	88.0	3	12.0
South Carolina	198	175	88.4	23	11.6
South Dakota	7	7	100	0	0.0
Tennessee	206	160	77.7	46	22.3
Texas	1,244	1,047	84.2	197	15.8
Utah	58	37	63.8	21	36.2
Vermont	3	3	100	0	0.0
Virginia	220	184	83.6	36	16.4
Washington	136	122	89.7	14	10.3
West Virginia ^a	30	24	80.0	6	20.0
Wisconsin	61	51	83.6	10	16.4
Wyoming	2	2	100	0	0.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are for cases reported to CDC through June 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

^a Data should be interpreted with caution due to a lapse in laboratory data completeness that occurred during the year 2022.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2023				
Arizona					
Maricopa County	634	535	84.4	99	15.6
California					
Alameda County	186	163	87.6	23	12.4
Los Angeles County	1,564	1,328	84.9	236	15.1
Orange County	262	236	90.1	26	9.9
Riverside County	299	244	81.6	55	18.4
Sacramento County	141	125	88.7	16	11.3
San Bernardino County	279	205	73.5	74	26.5
San Diego County	381	333	87.4	48	12.6
San Francisco County	184	175	95.1	9	4.9
District of Columbia	187	157	84.0	30	16.0
Florida					
Broward County	568	453	79.8	115	20.2
Duval County	259	200	77.2	59	22.8
Hillsborough County	362	302	83.4	60	16.6
Miami-Dade County	1,045	861	82.4	184	17.6
Orange County	477	400	83.9	77	16.1
Palm Beach County	277	227	81.9	50	18.1
Pinellas County	155	122	78.7	33	21.3
Georgia					
Cobb County	164	139	84.8	25	15.2
DeKalb County	305	257	84.3	48	15.7
Fulton County	444	367	82.7	77	17.3
Gwinnett County	233	201	86.3	32	13.7
Illinois					
Cook County	949	816	86.0	133	14.0
Indiana					
Marion County	258	217	84.1	41	15.9
Louisiana					
East Baton Rouge Parish	127	104	81.9	23	18.1
Orleans Parish	128	106	82.8	22	17.2
Maryland					
Baltimore City	165	153	92.7	12	7.3
Montgomery County	98	87	88.8	11	11.2
Prince George's County	193	173	89.6	20	10.4
Massachusetts					
Suffolk County	142	131	92.3	11	7.7
Michigan					
Wayne County	294	227	77.2	67	22.8
Nevada					
Clark County	498	413	82.9	85	17.1
New York					
Bronx County	411	346	84.2	65	15.8
Kings County	475	386	81.3	89	18.7
New York County	301	251	83.4	50	16.6
Queens County	434	390	89.9	44	10.1

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2023 (cont)					
North Carolina					
Mecklenburg County	272	230	84.6	42	15.4
Ohio					
Cuyahoga County	146	125	85.6	21	14.4
Franklin County	209	183	87.6	26	12.4
Hamilton County	105	89	84.8	16	15.2
Pennsylvania					
Philadelphia County	373	320	85.8	53	14.2
Tennessee					
Shelby County	352	221	62.8	131	37.2
Texas					
Bexar County	390	315	80.8	75	19.2
Dallas County	842	667	79.2	175	20.8
Harris County	1,322	1,054	79.7	268	20.3
Tarrant County	342	279	81.6	63	18.4
Travis County	219	201	91.8	18	8.2
Washington					
King County	177	154	87.0	23	13.0
Total	17,628	14,668	83.2	2,960	16.8
2024 (January–March)					
Arizona					
Maricopa County	169	153	90.5	16	9.5
California					
Alameda County	49	44	89.8	5	10.2
Los Angeles County	318	265	83.3	53	16.7
Orange County	58	54	93.1	4	6.9
Riverside County	67	53	79.1	14	20.9
Sacramento County	7	6	85.7	1	14.3
San Bernardino County	50	37	74.0	13	26.0
San Diego County	84	76	90.5	8	9.5
San Francisco County	45	44	97.8	1	2.2
District of Columbia	14	12	85.7	2	14.3
Florida					
Broward County	168	139	82.7	29	17.3
Duval County	77	60	77.9	17	22.1
Hillsborough County	95	80	84.2	15	15.8
Miami-Dade County	305	253	83.0	52	17.0
Orange County	147	129	87.8	18	12.2
Palm Beach County	88	74	84.1	14	15.9
Pinellas County	56	46	82.1	10	17.9
Georgia					
Cobb County	41	35	85.4	6	14.6
DeKalb County	83	73	88.0	10	12.0
Fulton County	141	120	85.1	21	14.9
Gwinnett County	68	56	82.4	12	17.6
Illinois					
Cook County	235	208	88.5	27	11.5

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2023 through March 2024—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2024 (January–March) (<i>cont</i>)					
Indiana					
Marion County	86	75	87.2	11	12.8
Louisiana					
East Baton Rouge Parish	37	32	86.5	5	13.5
Orleans Parish	37	34	91.9	3	8.1
Maryland					
Baltimore City	45	43	95.6	2	4.4
Montgomery County	25	24	96.0	1	4.0
Prince George's County	54	50	92.6	4	7.4
Massachusetts					
Suffolk County	17	17	100	0	0.0
Michigan					
Wayne County	86	76	88.4	10	11.6
Nevada					
Clark County	136	120	88.2	16	11.8
New York					
Bronx County	113	101	89.4	12	10.6
Kings County	163	143	87.7	20	12.3
New York County	90	81	90.0	9	10.0
Queens County	98	85	86.7	13	13.3
North Carolina					
Mecklenburg County	81	67	82.7	14	17.3
Ohio					
Cuyahoga County	40	39	97.5	1	2.5
Franklin County	45	39	86.7	6	13.3
Hamilton County	20	19	95.0	1	5.0
Pennsylvania					
Philadelphia County	112	92	82.1	20	17.9
Tennessee					
Shelby County	73	49	67.1	24	32.9
Texas					
Bexar County	80	67	83.7	13	16.3
Dallas County	258	210	81.4	48	18.6
Harris County	347	295	85.0	52	15.0
Tarrant County	105	90	85.7	15	14.3
Travis County	65	60	92.3	5	7.7
Washington					
King County	62	55	88.7	7	11.3
Total	4,640	3,980	85.8	660	14.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through June 2024, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

Table 3. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico^a	Alabama
Maricopa County	San Juan Municipio ^a	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey^a		
Essex County ^a		
Hudson County ^a		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 3. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

^a Linkage to care data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey and Puerto Rico.